1. Pink Sheet
  2. >>Legislation

Increased FDA China Inspections Backed By House Panel, While Purse Strings Pulled Still Tighter

 
• By Cathy Dombrowski

Funds for the Reagan-Udall Foundation must come from the FDA commissioner’s office account, under successful amendment from Rep. DeLauro.

The House Appropriations Committee is endorsing FDA’s plan to spend $10 million more on inspections in China in 2013, but unlike its Senate counterpart, is not increasing the agency’s overall budget to help do so.

The House panel actually proposes to fund FDA with less than it requested, and in a report on its appropriations bill, does not specify from where else in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Pink Sheet

Few Takers For EMA’s OPEN Pathway Prompts Rethink

 
• By Vibha Sharma

While drug companies say they support the European Medicines Agency’s expanded OPEN framework for the collaborative assessment of marketing applications with non-EU authorities, they are reluctant to participate in the initiative for a number of reasons.

EU Council Could Adopt Pharma Reform Package Next Week, But Disputes Risk A Year’s Delay

 
• By Eliza Slawther

The Council of the EU wants to adopt its negotiating position on the reform of the general pharmaceutical legislation “sooner, rather than later,” but divergence between member states could push negotiations back another year, a European Commission policy officer said today.

EU HTA Regulation: How Rare Disease Drug Makers Can Meet Worrisome JCAs Data Requirements

 
• By Francesca Bruce

In an interview with the Pink Sheet, Fonadazione Telethon’s Stefano Benvenuti discusses how companies developing and marketing rare disease treatments can overcome the challenges presented by EU-joint clinical assessment evidence requirements.